Compare JMIA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JMIA | SPRY |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.0M | 823.2M |
| IPO Year | 2018 | 2020 |
| Metric | JMIA | SPRY |
|---|---|---|
| Price | $7.07 | $7.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $16.75 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 3.1M | 1.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $22.18 | $87.40 |
| Revenue Next Year | $23.26 | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.89 | $6.66 |
| 52 Week High | $14.72 | $18.63 |
| Indicator | JMIA | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 35.06 |
| Support Level | $6.70 | $6.66 |
| Resistance Level | $9.49 | $8.61 |
| Average True Range (ATR) | 0.50 | 0.52 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 14.50 | 14.57 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.